Treatment of osteochondral defects of the talus.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 14. J Clin Orthop Trauma. 2016 Jul-Sep;7(3):153-6. doi: 10.1016/j.jcot.2016.05.004. Epub 2016 Jun 16. Autologous bone-marrow mesenchymal cell induced chondrogenesis (MCIC). Huh SW(1), Shetty AA(2), Ahmed S(2), Lee DH(1), Kim SJ(1). Author information: (1)Department of Orthopaedic Surgery, College of Medicine, The Catholic University of Korea, Republic of Korea. (2)Canterbury Christ Church University, Faculty of Health and Social Sciences, 30 Pembroke Court, Chatham Maritime, Kent ME4 4UF, United Kingdom. Degenerative and traumatic articular cartilage defects are common, difficult to treat, and progressive lesions that cause significant morbidity in the general population. There have been multiple approaches to treat such lesions, including arthroscopic debridement, microfracture, multiple drilling, osteochondral transplantation and autologous chondrocyte implantation (ACI) that are currently being used in clinical practice. Autologous bone-marrow mesenchymal cell induced chondrogenesis (MCIC) is a single-staged arthroscopic procedure. This method combines a modified microfracture technique with the application of a bone marrow aspirate concentrate (BMAC), hyaluronic acid and fibrin gel to treat articular cartilage defects. We reviewed the current literatures and surgical techniques for mesenchymal cell induced chondrogenesis. DOI: 10.1016/j.jcot.2016.05.004 PMCID: PMC4949404